The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
The Food and Drug Administration on Thursday approved Amgen's treatment for patients with the most deadly form of lung cancer. The agency cleared the drug, called Imdelltra, as a second or later ...
The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has progressed following ...
May 16 (Reuters) - (This May 16 story has been officially corrected by Amgen to change the pricing estimate in paragraph 4) The U.S. Food and Drug Administration on Thursday granted accelerated ...
La Food and Drug Administration des États-Unis a approuvé mardi le Bkemv d'Amgen, le premier biosimilaire de Soliris, le traitement d'AstraZeneca contre les maladies sanguines rares. Le ...
The US Food and Drug Administration (FDA) has approved Amgen's Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) for the treatment of specific rare diseases.
FRIDAY, MAY 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat ...
Vendredi, les analystes d'Oppenheimer ont maintenu les perspectives positives d' Amgen Inc . (NASDAQ:AMGN), avec une réitération de la note "Outperform" et un objectif de prix stable de 380,00 $. Cet ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly, tarlatamab (Imdelltra) is only for patients who ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. The U.S. Food and Drug Administration on Thursday approved a new ...